Worth reading
65In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
18.8
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFiscal year ending March 2026, full year13 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥10,796 million+18.8%
Operating profit¥454 million-1.6%
Ordinary income¥421 million+20.2%
Net income¥253 million+39.2%
Gross Profit Margin57.7 %
Operating profit margin4.2 %
Results for the three months of the current quarter
Fourth quarter of the fiscal year ending March 2026 (January–March 2026)
Net Sales
¥2,821 million+9.5%
Operating profit
¥268 million+110.9%
Ordinary income
¥261 million+130.4%
Net income
¥244 million+724.4%
Gross Profit Margin
59.7 %
Year-on-year change (points)1.6
Full-year earnings forecast
Fiscal year ending March 2026
Net Sales
¥11,000 million
EBITDA
¥1,200 million
Operating profit
¥610 million
Ordinary income
¥560 million
Profit attributable to owners of the parent
¥320 million
Fiscal year ending March 2027
Net Sales
¥12,000 million
EBITDA
¥1,200 million
Operating profit
¥610 million
Ordinary income
¥560 million
Profit attributable to owners of the parent
¥350 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales98.2 %
EBITDA86.9 %
Operating profit74.4 %
Ordinary income75.2 %
Profit attributable to owners of the parent79.2 %
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Revenue was broadly in line with the plan, while EBITDA and lower-level profit metrics fell short of the forecastBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Consolidation and growth of ONE MEDICALDetailsMade a significant contribution to revenue growth
- Upfront investment in the Medical businessDetailsReduced operating profit
- Decline in advertising rates in Media ServicesDetailsFactor behind lower revenue and profit
- Profit growth in the counseling services businessDetailsContributed to profit growth
- M&A BrokerageDetailsContributed to profit
- Head office relocation costs¥68 million
- Business Withdrawal Losses¥43 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
- AssumptionsConcentrate investment in growth businesses in the first half
- AssumptionsOperating profit is expected to be weighted toward the second half
- AssumptionsAdvertising and promotional expenses are expected to represent approximately 60% of revenue after market share expansion
New initiatives
- ONE MEDICAL to fully launch its diet and pharmaceutical wholesale businesses
- Concentrate investment in growth businesses in the first half
- Reduce personnel and outsourcing costs through AI-enabled digital transformation
- Merge and integrate the DX business into エキサイト in April 2026
Key KPIsA metric the company considers important as a management benchmark.
- Repeat customer ratio75.3 %Year on year against the same period last yearUp from 69.2% in the previous fiscal year
- Average monthly page views for Media ServicesAmount not stated-7.1%
- Average monthly paying subscribers62,316 people+0.2%
- SaaS business ARR¥558 million+27.3%
- Cosmetic medicine market size6,300 Hundreds of millions of yen
Segment results
- Medical BusinessNet Sales2,874Revenue unit¥ millionRevenue YoY (%)200.1Operating profit-155Operating profit unit¥ millionOperating profit yoy_value-160
- Platform BusinessNet Sales3,396Revenue unit¥ millionRevenue YoY (%)-2.5Operating profit549Operating profit unit¥ millionOperating Profit YoY (%)1.5
- Broadband businessNet Sales3,613Revenue unit¥ millionRevenue YoY (%)-2.8Operating profit543Operating profit unit¥ millionOperating Profit YoY (%)-3.3
- SaaS and DX businessNet Sales915Revenue unit¥ millionRevenue YoY (%)-1.9Operating profit-68Operating profit yoy_value6
Medium-term management plan targets
The presentation states that the fiscal year ending March 2027 will be the final year of the medium-term management plan, with investment concentrated in priority areas and efforts to strengthen the profit-generation capabilities of cash cow businesses. Specific medium-term target figures: Not disclosed.Financial targets
DOE guideline4 %
Actual equity ratio32.3 %
Equity ratio unit%
Actual ROE7.2 %
ROEunit%
Market Size / Share
- Cosmetic medicine6,300 Hundreds of millions of yen
- 2025 internet advertising expenditure40,459 Hundreds of millions of yenYear on year+110.8%Share50.2
Number of employees
232 people
As ofEnd of March 2026
Annual Dividend
Fiscal year ending March 2026¥31.5 per share
Forecast for the fiscal year ending March 2027¥32.7 per share
Payout ratio
Total payout ratio
Fiscal year ending March 2025116.2 %
Fiscal year ending March 202698.4 %
Forecast for the fiscal year ending March 2027To be determined
Acquisition of treasury shares
Fiscal year ending March 2025¥65 million
Fiscal year ending March 2026¥97 million
Forecast for the fiscal year ending March 2027To be determined
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | Fiscal year ending March 2026, full year |
| Net Sales | ¥10,796 million (YoY +18.8%) |
| Operating profit | ¥454 million (YoY -1.6%) |
| Ordinary income | ¥421 million (YoY +20.2%) |
| Net income | ¥253 million (YoY +39.2%) |
| Gross Profit Margin | 57.7 % |
| Operating profit margin | 4.2 % |
| Results for the three months of the current quarter | Subject Fourth quarter of the fiscal year ending March 2026 (January–March 2026) / Net Sales ¥2,821 million (YoY +9.5%) / Operating profit ¥268 million (YoY +110.9%) / Ordinary income ¥261 million (YoY +130.4%) / Net income ¥244 million (YoY +724.4%) / Gross Profit Margin 59.7 % |
| Full-year earnings forecast | Fiscal year ending March 2026 Net Sales ¥11,000 million / EBITDA ¥1,200 million / Operating profit ¥610 million / Ordinary income ¥560 million / Profit attributable to owners of the parent ¥320 million / Fiscal year ending March 2027 Net Sales ¥12,000 million / EBITDA ¥1,200 million / Operating profit ¥610 million / Ordinary income ¥560 million / Profit attributable to owners of the parent ¥350 million |
| Progress against full-year forecast | Net Sales 98.2 % / EBITDA 86.9 % / Operating profit 74.4 % / Ordinary income 75.2 % / Profit attributable to owners of the parent 79.2 % |
| Self-assessment against the plan | Revenue was broadly in line with the plan, while EBITDA and lower-level profit metrics fell short of the forecast |
| Segment results | Segment Medical Business / Net Sales 2,874 / Revenue unit ¥ million / Revenue YoY (%) 200.1 / Operating profit -155 / Operating profit unit ¥ million / Operating profit yoy_value -160, Segment Platform Business / Net Sales 3,396 / Revenue unit ¥ million / Revenue YoY (%) -2.5 / Operating profit 549 / Operating profit unit ¥ million / Operating Profit YoY (%) 1.5, Segment Broadband business / Net Sales 3,613 / Revenue unit ¥ million / Revenue YoY (%) -2.8 / Operating profit 543 / Operating profit unit ¥ million / Operating Profit YoY (%) -3.3, Segment SaaS and DX business / Net Sales 915 / Revenue unit ¥ million / Revenue YoY (%) -1.9 / Operating profit -68 / Operating profit yoy_value 6 |
| Breakdown of Factors Affecting the Change | Factors Consolidation and growth of ONE MEDICAL / Details Made a significant contribution to revenue growth, Factors Upfront investment in the Medical business / Details Reduced operating profit, Factors Decline in advertising rates in Media Services / Details Factor behind lower revenue and profit, Factors Profit growth in the counseling services business / Details Contributed to profit growth, Factors M&A Brokerage / Details Contributed to profit, Factors Head office relocation costs / Amount ¥68 million, Factors Business Withdrawal Losses / Amount ¥43 million |
| Key KPIs | Repeat customer ratio 75.3 %, Average monthly page views for Media Services 非開示 (YoY -7.1%), Average monthly paying subscribers 62,316 people (YoY +0.2%), SaaS business ARR ¥558 million (YoY +27.3%), Cosmetic medicine market size 6,300 Hundreds of millions of yen |
| Number of employees | 232 people |
| Assumptions Underlying the Business Outlook | Assumptions Concentrate investment in growth businesses in the first half, Assumptions Operating profit is expected to be weighted toward the second half, Assumptions Advertising and promotional expenses are expected to represent approximately 60% of revenue after market share expansion |
| Medium-term management plan targets | The presentation states that the fiscal year ending March 2027 will be the final year of the medium-term management plan, with investment concentrated in priority areas and efforts to strengthen the profit-generation capabilities of cash cow businesses. Specific medium-term target figures: Not disclosed. |
| Financial targets | DOE guideline 4 % / Actual equity ratio 32.3 % / Equity ratio unit % / Actual ROE 7.2 % / ROEunit % |
| Annual Dividend | Fiscal year ending March 2026 ¥31.5 per share / Forecast for the fiscal year ending March 2027 ¥32.7 per share / Interim Dividend Not disclosed / Year-end dividend Not disclosed |
| Payout ratio | Total payout ratio Fiscal year ending March 2025 116.2 % / Fiscal year ending March 2026 98.4 % / Forecast for the fiscal year ending March 2027 To be determined / Payout ratio Not disclosed |
| Acquisition of treasury shares | Fiscal year ending March 2025 ¥65 million / Fiscal year ending March 2026 ¥97 million / Number of Shares Not disclosed / Period Not disclosed / Forecast for the fiscal year ending March 2027 To be determined |
| Market Size / Share | Market Cosmetic medicine / Market Size 6,300 Hundreds of millions of yen, Market 2025 internet advertising expenditure / Market Size 40,459 Hundreds of millions of yen / Year on year 110.8 Hundreds of millions of yen / Share 50.2 Hundreds of millions of yen |
| New initiatives | ONE MEDICAL to fully launch its diet and pharmaceutical wholesale businesses, Concentrate investment in growth businesses in the first half, Reduce personnel and outsourcing costs through AI-enabled digital transformation, Merge and integrate the DX business into エキサイト in April 2026 |
Items this document does not state (7)
Selling, general and administrative expensesUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue benefited significantly from the consolidation of ONE MEDICAL, which was acquired in November 2024. Operating profit was affected by upfront investment to support future growth in the Medical business, as well as weakness in Media Services during the first half. In the fourth quarter, growth in the Medical business and improved profitability in Media Services contributed to results.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.